Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market

Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market


  • Products Id :- KR453
  • |
  • Pages: 159
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Ken Research announced its latest publication on "Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market" provides a comprehensive analysis of the anticoagulants market. The report includes the cumulative revenue generated by the market players from the sales of anticoagulants, including both generic and patented drugs at manufacturer's price and market share contributed by the sales of heparin, NOACs, Vitamin K Antagonists, and Injectable Direct Inhibitors in the total anticoagulants market. Further, the market in the study is differentiated on the basis of route of administration into oral and injectable. The market is also segmented by four geographical regions across the globe – North America, Europe, Asia Pacific, and Rest of the World. Detailed snapshot on key regions of the Market which includes North America, Europe, and Asia Pacific is included in the report to elucidate facts about the market in detail. The study also highlights the detailed information about major drug manufacturers in the global anticoagulants market and their respective shares by revenue in 2015. Analysis on patented drugs available in the market, and their approval procedure, timeline, and expected expiries is provided in report to assist new entrants in understanding the market before investing in the market. Various marketing analysis factors such as trends and developments and Porter's five forces analysis are also added in the study for clear understanding about the factors responsible for present scenario of the market. The future analysis of overall global anticoagulants market has also been discussed along with recommendations from analyst view.

Global Anticoagulants Market
Anticoagulants being the major part of the first line treatment of heart diseases including atrial fibrillation, deep vein thrombosis, pulmonary embolism, and stroke have been used extensively across the globe. Moreover, growing prevalence of coagulation disorders coupled with the aging population has increased the demand for anticoagulant drugs consequently leading to increased revenue generation. Launch of four patented drugs in the market in newly formed anticoagulants drug class, novel oral anticoagulants (NOACs) in between 2008 and 2014 has also resulted in high revenue generation for the total anticoagulants market as patented drugs are expensive in nature. Global anticoagulants market has been valued at USD ~ million in 2013 which increased to USD ~ million in 2015, exhibiting a CAGR of ~% in between 2013 and 2015.

Global Anticoagulants Market Segmentation
On the basis of type, heparin dominated the anticoagulants market with revenue share of ~% in 2015. Application of the heparin in wide therapeutic indications including venous thromboembolism, extracorporeal circuit procedure, and treatment of disseminated intravascular coagulation is the major factor which has led to the domination of heparin in the market. NOACs followed the heparin market in the global anticoagulants market with revenue share of ~% in 2015. The segment is also estimated as the fastest growing segment in the market. Flexibility to consume the drugs orally in comparison to injectables coupled with the presence of patented drugs in the market is the major factor which has driven the market for NOACs globally. Among the four patented drugs available in the NOAC category in the market, Bayer's Xarelto has been observed to generate maximum sales providing company domination over other players.

By route of administration, injectable anticoagulants dominated the anticoagulants market with revenue share of ~% in 2015 owing to the availability of heparins and direct inhibitors in injectable state only. Heparins being oldest type of anticoagulants known are approved in all countries across the globe, which is one of the major factors driving the market for injectable anticoagulants. However, the segment is slowly losing revenue share owing to the increasing demand for oral anticoagulants due to ease of consumption and effective results. 

By geographical regions, North America dominated the market with revenue share of ~% in 2015. High prevalence of coagulation disorders including atrial fibrillation, DVT and PE, presence of pharmaceutical giants, high awareness among people and economic stability to undergo expensive treatment options are the major factors which have driven the anticoagulants market in North America. Centers for Disease Control and Prevention estimated that approximately ~ to ~ million people in the US had atrial fibrillation in 2015 and with aging population, number is expected to increase. The statistics clearly advocates the high demand for anticoagulants in the region. Asia Pacific is estimated as the most opportunistic region in the market. High population in the country coupled with rising awareness and purchasing power of the people especially in India and China is assisting the region to grow at a rapid pace.

Competitive Scenario
Bayer dominated the global anticoagulants market in 2015 with revenue share of ~% in 2015. The advantage of owning the oldest type of patented NOAC, Xarelto in the market resulting in associated trust factor with the drug is the major factor which has helped the company in gaining high revenue share in the market. Sanofi with its Lovenox or Clexane in LMWH category captures second position in the market with revenue share of ~% in 2015. High popularity of the drug with wide patient pool of almost ~ million patients in more than 100 countries is the major factor which has helped company in generating high revenue in the market.

Key Topics Covered in the Report:

  • The market size of Global Anticoagulants Market
  • Market segmentation of Global Anticoagulants Market on the basis of Type, Route of Administration, and Geographical Analysis
  • Snapshot on North America Anticoagulants Market
  • Snapshot on Europe Anticoagulants Market
  • Snapshot on Asia Pacific Anticoagulants Market
  • Porter's Five Forces Analysis for Global Anticoagulants Market
  • Trends and Developments in Global Anticoagulants Market
  • NOACs Drug Approval Timeline
  • NOACs Patent Expiries
  • Competitive Landscape and Detailed Company Profiles of the Major Market Players
  • Future Outlook and Projections of Global Anticoagulants Market
  • Analyst Recommendations
  • Macro-Economic Factors Impacting the Global Anticoagulants Market


Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1. Executive Summary
Market Potential
Market Segmentation
Competitive Landscape
Future Outlook and Projections
2. Research Methodology
2.1. Market Definitions
2.2. Abbreviations
2.3. Market Size and Modeling
Approach - Market Sizing
Limitations
3. Introduction to Anticoagulants
Uses
Side Effects of Anticoagulants
4. Value Chain Analysis of Global Anticoagulants Market
5. Global Anticoagulants Market Size, 2013 - 2015
6. Global Anticoagulants Market Segmentation
6.1. By Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors), 2015
6.1.1. Heparin Market Segmentation by Type (Unfractionated and Low Molecular Weight Heparin)
6.1.2. NOACs Market Segmentation by Type (Rivaroxaban, Apixaban, Dabigatran Etexilate, and Edoxaban)
Drug Approval Timelines
Patent Expiries
6.2. By Route of Administration (Oral and Injectables)
6.3. By Geographical Regions (North America, Europe, Asia Pacific, and Rest of the World)
7. Snapshot on North America Anticoagulants Market
By Countries (US and Canada)
7.1. US Market Indicators
7.1.1. US Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors)
7.1.2. Key Anticoagulants in US
7.1.3. Regulatory Landscape
New Drug Approval Procedure
New Drug Timeline
Generic Drug Approval Procedure
Patents
Exclusivity
Anticoagulants Reimbursement Scenario in the US
7.2. Canada Market Indicators
7.2.1. Canada Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors)
7.2.2. Cost of Key Anticoagulants in Canada
7.2.1. Market Share of Major Players (Bayer Inc., Boehringer Ingelheim, and Bristol-Myers Squibb Canada Co) in Canada Anticoagulants Market, 2015
7.2.2. Regulatory Landscape
Generic Drug Approval Procedure
Patents and Exclusivity
Pharmaceutical Pricing and Reimbursement in Canada
8. Snapshot on Europe Anticoagulants Market
8.1. By Countries (Germany, France, Spain, Italy, UK, and Rest of the Europe)
8.2. Europe Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors)
8.2.1. Cost of Key Anticoagulants in Europe
8.3. Europe Anticoagulants Market by Companies (Bayer Inc., Boehringer Ingelheim, Pfizer, and Others)
8.4. Regulatory Landscape
8.4.1. New Drug Approval Procedure
8.4.2. Patents
8.4.3. Reimbursement Scenario in Europe
9. Snapshot on Asia Pacific Anticoagulants Market
By Countries (Japan, Australia, China, India, and Rest of the Asia Pacific)
9.1. Japan Market Indicators
9.1.1. Japan Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors)
9.1.2. Key Anticoagulants in Japan
9.1.3. Regulatory Landscape
New Drug Approval Procedure
Patents
9.2. Australia Market Indicators
9.2.1. Australia Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors)
9.2.2. Cost of Key Anticoagulants in Australia
9.2.3. Regulatory Landscape
New Drug Approval Procedure
Patents
Reimbursement Scenario in Australia
9.3. China Market Indicators
9.3.1. China Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors)
9.3.2. Cost of Key Anticoagulants in China
9.3.3. Market Share of Major Players (Bayer China, Boehringer Ingelheim, and Others) in China Anticoagulants Market, 2015
9.3.4. Regulatory Landscape
New Drug Approval Procedure
Patents
9.4. India Market Indicators
9.4.1. India Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors)
9.4.1. Cost of Key Anticoagulants in India
9.4.2. Market Share of Major Players (Bayer India, Boehringer Ingelheim, Pfizer, GSK Pharmaceutical Ltd., Aventis Pharma and Others) in India Anticoagulants Market
9.4.3. Regulatory Landscape
New Drug Approval Procedure
Patents
Pricing and Reimbursement Scenario in India
10. Porter’s Five Forces Analysis for Global Anticoagulants Market
11. Trends and Developments in Global Anticoagulants Market
11.1. Expanding Therapeutic Indication
11.2. High incidence rate of DVT/PE
11.3. Disadvantages of Patented NOACs over Generic VKAs and Heparin Impacting Market Negatively
12. Global Anticoagulants Market Competitive Landscape
12.1. Market Share of Key Players in Global Anticoagulants Market, 2015
12.2. Company Profiles for Key Manufacturers in Anticoagulants Market
12.2.1. Sanofi
12.2.2. Pfizer Inc.
12.2.3. Boehringer Ingelheim
12.2.4. Bayer AG
12.2.5. Bristol-Myers Squibb Company
12.2.6. Daichi Sankyo company, Limited
13. Future of Global Anticoagulants Market
13.1. Future Outlook and Projections, 2016 - 2020
14. Analyst Recommendations
15. Macroeconomic Indicators
15.1. Aging Population
15.2. Deaths from Cardiovascular Diseases, 2010 - 2020
15.3. Healthcare Spending, 2010 - 2020
Disclaimer
Contact Us

Table 4-1: Role of Various Stakeholders in the Value Chain of Global Anticoagulants Market
Table 5-1: Global Anticoagulants Market and Rationale for Revenue, 2013 - 2015
Table 6-1: Global Anticoagulants Market by Type (Heparin, Novel Oral Anticoagulants, Vitamin K Antagonists, and Injectable Direct Inhibitors) and Rationale for Revenue, 2015
Table 6-2: Comparison of Commonly Prescribed Anticoagulants on the basis of Indication, Dosing, Route of Administration, Dosage Modifications, and Cost of Treatment
Table 6-3: Global Anticoagulants Market Segmentation by Type (Heparin, Novel Oral Anticoagulants, Vitamin K Antagonists, and Injectable Direct Inhibitors) on the basis of Revenue in USD Million, 2013 - 2015
Table 6-4: Global Heparin Market by Type (Unfractionated and Low Molecular Weight Heparin) and Rationale for Revenue, 2015
Table 6-5: Key Heparin Drugs and their Generic Name, Route of Administration and Price
Table 6-6: Global Heparin Market Segmentation by Type (Unfractionated and Low Molecular Weight Heparin) on the basis of Revenue in USD Million, 2013 - 2015
Table 6-7: Global NOACs Market by Type (Rivaroxaban, Apixaban, Dabigatran Etexilate, and Edoxaban) and Rationale for Revenue, 2015
Table 6-8: Comparative Analysis of NOACs on the basis of Bioavailability, Time to Cmax, Half Life, Drug Interaction Concerns, Adjustment for Renal Function, Other Adjustments, Bleed Rates, Major or Common Side Effects, Effects on Common Coagulation Labs, Dosing Frequency and Unique Point
Table 6-9: Rivaroxaban Approval Timeline
Table 6-10: Apixaban Approval Timeline
Table 6-11: Edoxaban Approval Timeline
Table 6-12: Dabigatran Etexilate Approval Timeline
Table 6-13: Patent Expiries of NOACs by Countries
Table 6-14: Global NOACs Market Segmentation by Type (Rivaroxaban, Apixaban, Dabigatran Etexilate, and Edoxaban) on the basis of Revenue in USD Million, 2013 - 2015
Table 6-15: Global Anticoagulants Market by Route of Administration (Oral and Injectables) and Rationale for Revenue, 2015
Table 6-16: Global Anticoagulants Market Segmentation by Route of Administration (Oral and Injectable) on the basis of Revenue in USD Million, 2013 - 2015
Table 6-17: Global Anticoagulants Market by Geographical Regions (North America, Europe, Asia Pacific and Rest of the World) and Rationale for Revenue, 2013 - 2015
Table 6-18: Global Anticoagulants Market Segmentation by Geographical Regions (North America, Europe, Asia Pacific and Rest of the World) on the basis of Revenue in USD Million, 2013 - 2015
Table 7-1: Snapshot on North America Anticoagulants Market
Table 7-2: North America Anticoagulants Market Segmentation by Countries (US and Canada) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 7-3: Prevalence of Major Disease Indications for which Anticoagulants are used in the US
Table 7-4: US Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 7-5: Key Branded Drugs in the US, Company and their Sales in terms of USD Million, 2013 - 2015
Table 7-6: US Anticoagulants Market Segmentation by Companies (Janssen Pharmaceuticals, Bristol-Myers Squibb, Boehringer Ingelheim, Sanofi, and Others) on the basis of Revenue, 2015
Table 7-7: Drug Approval Applications, Rationale, and Fees in the US, 2016
Table 7-8: Types of Drug Exclusivity, Rationale, and Time Period of Exclusivity
Table 7-9: Prevalence of Major Disease Indications for which Anticoagulants are used in Canada
Table 7-10: Canada Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 7-11: Key Branded Anticoagulants in Canada, Company and its Average Price
Table 7-12: Canada Anticoagulants Market Segmentation by Companies (Bayer Inc., Boehringer Ingelheim, Bristol Myers Squibb Canada Co, and Others) on the basis of Revenue, 2015
Table 7-13: Patent and Exclusivity Procedure in Canada and Rationale
Table 8-1: Prevalence of Major Disease Indications for which Anticoagulants are used in Europe
Table 8-2: Snapshot on Europe Anticoagulants Market
Table 8-3: Europe Anticoagulants Market Segmentation by Countries (Germany, Spain, Italy, France, UK, and Rest of the Europe) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 8-4: Europe Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 8-5: Key Branded Anticoagulants in Europe, Company and its Average Price
Table 8-6: Europe Anticoagulants Market Segmentation by Companies (Bayer Inc., Boehringer Ingelheim, Bristol Myers Squibb, and Others) on the basis of Revenue, 2015
Table 8-7: Product Price Regulation in Europe by Countries, 2016
Table 8-8: Control of Expenditure in Europe by Countries, 2016
Table 8-9: Industry Regulations in Europe by Countries, 2016
Table 8-10: Product Reimbursement in Europe by Countries, 2016
Table 9-1: Snapshot on Asia Pacific Anticoagulants Market
Table 9-2: Asia Pacific Anticoagulants Market Segmentation by Countries (Japan, Australia, China, India, and Rest of the Asia Pacific) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 9-3: Prevalence of Major Disease Indications for which Anticoagulants are used in Japan
Table 9-4: Japan Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 9-5: Key Branded Anticoagulants in Japan, and Company
Table 9-6: Prevalence of Major Disease Indications for which Anticoagulants are used in Australia
Table 9-7: Australia Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 9-8: Key Branded Anticoagulants in Australia, Company and Average Price in USD
Table 9-9: Prevalence of Major Disease Indications for which Anticoagulants are used in China
Table 9-10: China Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 9-11: Key Branded Drugs in the China, Company. Price and their Estimated Sales in terms of USD Million, 2013 - 2015
Table 9-12: China Anticoagulants Market Segmentation by Companies (Bayer Inc., Boehringer Ingelheim, Bristol Myers Squibb, and Others) on the basis of Revenue, 2015
Table 9-13: Prevalence of Major Disease Indications for which Anticoagulants are used in India
Table 9-14: India Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 9-15: Key Branded Drugs in the India, Company. Price and their Estimated Sales in terms of USD Million, 2013 - 2015
Table 9-16: India Anticoagulants Market Segmentation by Companies (Bayer India, Boehringer Ingelheim, Pfizer, GSK Pharmaceutical Ltd., Aventis Pharma and Others) on the basis of Revenue, 2015
Table 10-1: Porter's Five Forces Analysis for Global Anticoagulants Market
Table 12-1: Global Anticoagulants Market by Manufacturers and Rationale for Revenue, 2015
Table 12-2: Global Anticoagulants Market Segmentation by Companies (Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb Company, Sanofi, Pfizer Inc., Janssen Pharmaceuticals and Others) on the Basis of Revenue, 2015
Table 12-3: Competitive Landscape of Sanofi including Company Overview, Global Footprints, Product Portfolio, Business Strategies, Number of Employees, and Key Personnel
Table 12-4: Competitive Landscape of Pfizer Inc. including Company Overview, Global Footprints, Product Portfolio, Business Strategies, Research and Development, Number of Employees, and Key Personnel
Table 12-5: Company Profile of Boehringer Ingelheim including Company Overview, Global Footprints, Business Strategies, and Number of Employees
Table 12-6: Company Profile of Bayer AG including Company Overview, Global Footprints, Business Strategies, and Number of Employees
Table 12-7: Company Profile of Bristol-Myers Squibb Company including Company Overview, Global Footprints, Business Strategies, and Number of Employees
Table 12-8: Company Profile of Daichi Sankyo Company, Limited including Company Overview, Global Footprints, Business Strategies, and Number of Employees
Table 13-1: Future Drivers for Global Anticoagulants Market
Table 13-2: Global Anticoagulants Market Segmentation Outlook and Future Projections by Type (Heparin, Novel Oral Anticoagulants, Vitamin K Antagonists, and Injectable Direct Inhibitors) on the basis of Revenue in USD Million, 2016 - 2020
Table 13-3: Global Anticoagulants Market Segmentation Outlook and Future Projections by Geographical Regions (North America, Europe, Asia Pacific, and Rest of the World) on the basis of Revenue in USD Million, 2016 - 2020
Table 14-1: Recommendations for Global Anticoagulants Market
Table 15-1: Rationale for Global Aging Population, 2010 - 2020
Table 15-2: Rationale for Global Deaths from Cardiovascular Diseases, 2010 - 2020
Table 15-3: Rationale for Global Healthcare Spending, 2010 - 2020

Table 4-1: Role of Various Stakeholders in the Value Chain of Global Anticoagulants Market
Table 5-1: Global Anticoagulants Market and Rationale for Revenue, 2013 - 2015
Table 6-1: Global Anticoagulants Market by Type (Heparin, Novel Oral Anticoagulants, Vitamin K Antagonists, and Injectable Direct Inhibitors) and Rationale for Revenue, 2015
Table 6-2: Comparison of Commonly Prescribed Anticoagulants on the basis of Indication, Dosing, Route of Administration, Dosage Modifications, and Cost of Treatment
Table 6-3: Global Anticoagulants Market Segmentation by Type (Heparin, Novel Oral Anticoagulants, Vitamin K Antagonists, and Injectable Direct Inhibitors) on the basis of Revenue in USD Million, 2013 - 2015
Table 6-4: Global Heparin Market by Type (Unfractionated and Low Molecular Weight Heparin) and Rationale for Revenue, 2015
Table 6-5: Key Heparin Drugs and their Generic Name, Route of Administration and Price
Table 6-6: Global Heparin Market Segmentation by Type (Unfractionated and Low Molecular Weight Heparin) on the basis of Revenue in USD Million, 2013 - 2015
Table 6-7: Global NOACs Market by Type (Rivaroxaban, Apixaban, Dabigatran Etexilate, and Edoxaban) and Rationale for Revenue, 2015
Table 6-8: Comparative Analysis of NOACs on the basis of Bioavailability, Time to Cmax, Half Life, Drug Interaction Concerns, Adjustment for Renal Function, Other Adjustments, Bleed Rates, Major or Common Side Effects, Effects on Common Coagulation Labs, Dosing Frequency and Unique Point
Table 6-9: Rivaroxaban Approval Timeline
Table 6-10: Apixaban Approval Timeline
Table 6-11: Edoxaban Approval Timeline
Table 6-12: Dabigatran Etexilate Approval Timeline
Table 6-13: Patent Expiries of NOACs by Countries
Table 6-14: Global NOACs Market Segmentation by Type (Rivaroxaban, Apixaban, Dabigatran Etexilate, and Edoxaban) on the basis of Revenue in USD Million, 2013 - 2015
Table 6-15: Global Anticoagulants Market by Route of Administration (Oral and Injectables) and Rationale for Revenue, 2015
Table 6-16: Global Anticoagulants Market Segmentation by Route of Administration (Oral and Injectable) on the basis of Revenue in USD Million, 2013 - 2015
Table 6-17: Global Anticoagulants Market by Geographical Regions (North America, Europe, Asia Pacific and Rest of the World) and Rationale for Revenue, 2013 - 2015
Table 6-18: Global Anticoagulants Market Segmentation by Geographical Regions (North America, Europe, Asia Pacific and Rest of the World) on the basis of Revenue in USD Million, 2013 - 2015
Table 7-1: Snapshot on North America Anticoagulants Market
Table 7-2: North America Anticoagulants Market Segmentation by Countries (US and Canada) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 7-3: Prevalence of Major Disease Indications for which Anticoagulants are used in the US
Table 7-4: US Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 7-5: Key Branded Drugs in the US, Company and their Sales in terms of USD Million, 2013 - 2015
Table 7-6: US Anticoagulants Market Segmentation by Companies (Janssen Pharmaceuticals, Bristol-Myers Squibb, Boehringer Ingelheim, Sanofi, and Others) on the basis of Revenue, 2015
Table 7-7: Drug Approval Applications, Rationale, and Fees in the US, 2016
Table 7-8: Types of Drug Exclusivity, Rationale, and Time Period of Exclusivity
Table 7-9: Prevalence of Major Disease Indications for which Anticoagulants are used in Canada
Table 7-10: Canada Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 7-11: Key Branded Anticoagulants in Canada, Company and its Average Price
Table 7-12: Market Share of Major Players (Bayer Inc., Boehringer Ingelheim, Bristol Myers Squibb Canada Co, and Others) in Canada Anticoagulants Market on the basis of Revenue, 2015
Table 7-13: Patent and Exclusivity Procedure in Canada and Rationale
Table 8-1: Prevalence of Major Disease Indications for which Anticoagulants are used in Europe
Table 8-2: Snapshot on Europe Anticoagulants Market
Table 8-3: Europe Anticoagulants Market Segmentation by Countries (Germany, Spain, Italy, France, UK, and Rest of the Europe) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 8-4: Europe Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 8-5: Key Branded Anticoagulants in Europe, Company and its Average Price
Table 8-6: Europe Anticoagulants Market Segmentation by Companies (Bayer Inc., Boehringer Ingelheim, Bristol Myers Squibb, and Others) on the basis of Revenue, 2015
Table 8-7: Product Price Regulation in Europe by Countries, 2016
Table 8-8: Control of Expenditure in Europe by Countries, 2016
Table 8-9: Industry Regulations in Europe by Countries, 2016
Table 8-10: Product Reimbursement in Europe by Countries, 2016
Table 9-1: Snapshot on Asia Pacific Anticoagulants Market
Table 9-2: Asia Pacific Anticoagulants Market Segmentation by Countries (Japan, Australia, China, India, and Rest of the Asia Pacific) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 9-3: Prevalence of Major Disease Indications for which Anticoagulants are used in Japan
Table 9-4: Japan Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 9-5: Key Branded Anticoagulants in Japan, and Company
Table 9-6: Prevalence of Major Disease Indications for which Anticoagulants are used in Australia
Table 9-7: Australia Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 9-8: Key Branded Anticoagulants in Australia, Company and Average Price in USD
Table 9-9: Prevalence of Major Disease Indications for which Anticoagulants are used in China
Table 9-10: China Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 9-11: Key Branded Drugs in the China, Company. Price and their Estimated Sales in terms of USD Million, 2013 - 2015
Table 9-12: Market Share of Major Players (Bayer Inc., Boehringer Ingelheim, Bristol Myers Squibb, and Others) in China Anticoagulants Market on the basis of Revenue, 2015
Table 9-13: Prevalence of Major Disease Indications for which Anticoagulants are used in India
Table 9-14: India Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 9-15: Key Branded Drugs in the India, Company. Price and their Estimated Sales in terms of USD Million, 2013 - 2015
Table 9-16: Market Share of Major Players (Bayer India, Boehringer Ingelheim, Pfizer, GSK Pharmaceutical Ltd., Aventis Pharma and Others) in India Anticoagulants Market on the basis of Revenue, 2015
Table 10-1: Porter’s Five Forces Analysis for Global Anticoagulants Market
Table 12-1: Global Anticoagulants Market by Manufacturers and Rationale for Revenue, 2015
Table 12-2: Market Share of Major Players (Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb Company, Sanofi, Pfizer Inc., Janssen Pharmaceuticals and Others) in Global Anticoagulants Market on the Basis of Revenue, 2015
Table 12-3: Competitive Landscape of Sanofi including Company Overview, Global Footprints, Product Portfolio, Business Strategies, Number of Employees, and Key Personnel
Table 12-4: Competitive Landscape of Pfizer Inc. including Company Overview, Global Footprints, Product Portfolio, Business Strategies, Research and Development, Number of Employees, and Key Personnel
Table 12-5: Company Profile of Boehringer Ingelheim including Company Overview, Global Footprints, Business Strategies, and Number of Employees
Table 12-6: Company Profile of Bayer AG including Company Overview, Global Footprints, Business Strategies, and Number of Employees
Table 12-7: Company Profile of Bristol-Myers Squibb Company including Company Overview, Global Footprints, Business Strategies, and Number of Employees
Table 12-8: Company Profile of Daichi Sankyo Company, Limited including Company Overview, Global Footprints, Business Strategies, and Number of Employees
Table 13-1: Future Drivers for Global Anticoagulants Market
Table 13-2: Global Anticoagulants Market Segmentation Outlook and Future Projections by Type (Heparin, Novel Oral Anticoagulants, Vitamin K Antagonists, and Injectable Direct Inhibitors) on the basis of Revenue in USD Million, 2016 - 2020
Table 13-3: Global Anticoagulants Market Segmentation Outlook and Future Projections by Geographical Regions (North America, Europe, Asia Pacific, and Rest of the World) on the basis of Revenue in USD Million, 2016 - 2020
Table 14-1: Recommendations for Global Anticoagulants Market
Table 15-1: Rationale for Global Aging Population, 2010 - 2020
Table 15-2: Rationale for Global Deaths from Cardiovascular Diseases, 2010 - 2020
Table 15-3: Rationale for Global Healthcare Spending, 2010 - 2020

Single User License:
Access to the soft copy of the report will be granted to individual user/ Authorized User within the organization The Authorized User may store, display or archive the information but will not be able to print, copy and use any information in the report for circulation or citation purpose. The individual user will treat the information in the report as confidential and will only use this for internal purpose. In no circumstance, the complete / part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view. The report will be MAC address protected and will only be accessible on 1 platform.

Hard Copy License:
The license provides the access to hard copy/ printed copy of the report to the Authorized User only. The report will be delivered to the user on the address provided during making the purchase. The Authorized User may store, display, or archive the information but will not use any information in the report for circulation or citation purpose. The individual user will treat the information in the report as confidential and will only use this for internal purpose. In no circumstance, the complete / part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view. No soft copy access will be provided in this case.

Corporate User License:
Access to the soft copy of the report will be granted to multiple users within the organization. The users are authorized to store, display, duplicate, archive, print and distribute the information within the organization either electronically or in paper. The users are not authorized to use any information in the report for citation and circulation externally. The users will treat the information in the report as confidential and will only use this for internal purpose. In no circumstance, the complete / part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view.

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Pfizer, Inc, Sanofi, Boehringer Ingelheim, Bayer AG, Bristol-Myers Squibb Company, Daichi Sankyo Company Limited, Janssen Pharmaceuticals

Xarelto, Eliquis, Lixiana/Savaysa, Pradaxa, Lovenox, Arixtra, Fragmin, Warfarin,

select a license

Single User License
USD 2500 INR 160650
Hard Copy License
USD 3000 INR 192780
Corporate User License
USD 5000 INR 321300

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com